Groups
Treatment/Dose (mg/mL)		 TG
(mg/dl)		 TC
(mg/dl)		 HDL-C
(mg/dl)		 LDL-C
(mg/dl)		 vLDL-C
(mg/dl)		 Atherogenic index
Normal Control 83.92
± 4.63		 102.73
±5.52		 37.6
± 5.84		 48,35
±4.95		 16.78
± 2.6		 0.348
±0.078
Control + CAMBA (25mg/kg) 79.27
±  5.81		 95.18
± 6.22		 34.21
± 4.69		 45.12
± 7.24		 15.85
±4.10		 0.364
±0.065
Control + CAMBA (25mg/kg) 76.56
± 6.09		 90.39
± 4.64		 39.07
± 6.24		 36.00
± 4.71		 15.31
± 3.6		 0.292
±0.049
Diabetic Control 157.34
±9.77**		 141.53
± 7.04**		 24.33
± 5.46**		 85.55
± 4.94**		 31.48
± 6.9**		 0.810
±0.083**
Diabetic +CAMBA (25mg/kg) 106.48
±  6.19**		 137.50
± 5.26**		 27.18
± 4.50**		 89.02
± 6.11**		 21.29
± 3.4**		 0.593
±0.046*
Diabetic +CAMBA (25mg/kg) 86.25
± 4.02**		 94.67
± 3.44**		 33.75
± 6.38**		 43.67
± 4.38**		 17.25
±4.2**		 0.407
±0.037**
Diabetic +Glibenclamide(5mg/kg) 77.28
± 6.86**		 92.58
± 8.15**		 35.02
± 7.53**		 42.10
±5.72**		 15.45
±3.6**		 0.344
±0.026**
Values represent the mean ± SE (n=8). Diabetic control rats were compared with normal control rats. Experimental groups were compared with the diabetic control rats LDL-C (mg/dl) = TC-HDL-[TG / 5], vLDL-C(mg/dl) = [Triglycerides/5], Atherogenic index = log (TG/HDL-C)
• *Significantly different from control group at p< 0.05
• **Significantly different from control group at p< 0.01
Table 4: Effect of CAMBA on plasma triglyceride (TG), total Cholesterol (TC), HDL-cholesterol (HDL-C), LDL- cholesterol (LDLC), vLDL- cholesterol (vLDLC) and atherogenic index in control and experimental groups of rats.